Società Italiana Talassemie ed Emoglobinopatie
8
2
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination Patients With Thalassemic and Falcemic Syndromes
Role: lead
Transfusion Treatment in Patients With SCD
Role: lead
Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19
Role: lead
STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY
Role: lead
A Nationwide Italian Survey on Asplenia
Role: lead
Vitamin D and Bisphosphonates in the Treatment of Sickle Cell Disease
Role: lead
Hydroxyurea in the Treatment of Sickle Cell Disease
Role: lead
Hepatitis C Virus Infection in Patients With Hemoglobinopathies
Role: lead
All 8 trials loaded